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Abstract 
Review on AKT1S1, with data on DNA/RNA, on the 
protein encoded and where the gene is implicated. 
Keywords 
AKT1S1, cancer, type 2 diabetes 
Identity 
Other names 
Lobe 
PRAS40 
HGNC (Hugo) 
AKT1S1 
Location 
19q13.33 
Note 
Akt1 substrate 1 (AKT1S1), also known as proline-
rich Akt substrate of 40-kDa (PRAS40) is a 
component of the Akt and mammalian target of 
rapamycin complex 1 (mTORC1) signaling cascades 
(Nascimento and Ouwens, 2009; Wang et al., 2012; 
Wiza et al., 2012). AKT1S1 can act as a negative 
regulator of the mTORC1 complex, and binds 
YWHAZ (14-3-3) when phosphorylated 
(Nascimento and Ouwens, 2009; Wang et al., 2012; 
Wiza et al., 2012). Several tumors and tumor cell 
lines display increased levels of phosphorylated 
AKT1S1 (Andersen et al., 2010; Huang and Porter, 
2005), but it is incompletely understood to what 
extent AKT1S1 participates in tumorigenesis. 
Finally, AKT1S1 function is critical for the 
regulation of insulin sensitivity in skeletal muscle 
(Wiza et al., 2014; Wiza et al., 2013a). 
Figure 1. Genomic location of the AKT1S1 gene at chromosome 19. 
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Figure 2. AKT1S1 transcript variants and isoforms. 
 
DNA/RNA 
Description 
The gene for AKT1S1 spans a genomic region of 
9324 bases, and is composed of seven exons. 
Transcription 
The gene encodes five transcript variants, which 
result in two protein isoforms. The longest one, 
transcript variant one, differs from the other variants 
in the 5' untranslated region and results in the 276 
amino acid protein isoform A. Transcript variants 2-
5 all result in the 256 amino acid protein isoform B. 
The gene for PRAS40 is ubiquitously expressed, but 
there is no information on changes in the expression 
of the various transcript variants among tissues and 
organs. 
Protein 
Note 
The protein encoded by the AKT1S1 gene has been 
identified as YWHAZ (also known as 14-3-3) 
binding protein in lysates from PC12 cells treated 
with epidermal growth factor or nerve growth factor, 
and was termed p39 (Harthill et al., 2002). This 
protein is identical to the YWHAZ-binding protein 
'proline-rich Akt-substrate of 40-kDa' purified from 
insulin-treated hepatoma cells (Kovacina et al., 
2003), and the nuclear phosphoprotein AKT1S1 
purified from HeLa cells (Beausoleil et al., 2004). 
Furthermore, AKT1S1 is a component of the 
cytosolic mammalian target of rapamycin complex 1 
(mTORC1) (Fonseca et al., 2007; Oshiro et al., 2007; 
Sancak et al., 2007; Thedieck et al., 2007; Vander 
Haar et al., 2007; Wang et al., 2007), and a nuclear 
complex containing the ribosomal protein L11 
(RPL11) (Havel et al., 2014). 
Description 
The AKT1S1 proteins occur as two single 
polypeptide chain proteins of 276 (isoform A) and 
256 (isoform B) amino acids, respectively. Isoform 
A differs from isoform B by a 20 amino acid 
extension at the amino terminus. Both isoforms share 
multiple conserved regions. At the amino terminus 
there are two proline-rich stretches with an as yet 
undefined function. These are followed by two short 
sequences, the TOS- and RAIP-motif that mediate 
the interaction with mTORC1 (Fonseca et al., 2007; 
Oshiro et al., 2007; Vander Haar et al., 2007; Wang 
et al., 2007). The FVMDE-stretch (amino acids 149-
153 of isoform A and amino acids 129-133 of 
isoform B) represents the TOS motif, while the 
KSLP-stretch (amino acids 202-205 of isoform A 
and 182-185 of isoform B) resembles the RAIP-
motif. Furthermore, the proteins contain a leucine-
enriched nuclear export sequence (amino acids 238-
247 of isoform A and amino acids 218-227 of 
isoform B) (Havel et al., 2014; Wiza et al., 2013b). 
Finally, AKT1S1 is phosphorylated on multiple sites 
(Wiza et al., 2012) (Figure 3). While Akt, Pim-1 and 
AGC-kinase have been linked to the phosphorylation 
of Thr266/Thr246 (isoform A and B, respectively), 
all other phosphorylations on AKT1S1 have been 
ascribed to mTORC1 (Figure 3). 
Expression 
The protein shows a ubiquitous expression, but there 
is no information available regarding the protein 
abundance of the two isoforms in various tissues and 
organs. 
Localisation 
The protein is found both in the cytosol and in the 
nucleus. The transport from the nucleus to the 
cytosol is mediated by the leucine-enriched nuclear 
export sequence at the carboxy terminus of the 
protein (Havel et al., 2014; Wiza et al., 2013b). 
Function 
Regulation of mTORC1 activity 
AKT1S1 acts as an inhibitor of mTORC1 activity 
(Wiza et al., 2012). Phosphorylation of AKT1S1 
results in the dissociation of the AKT1S1 from raptor 
within the mTORC1 complex thereby promoting the 
activity of mTORC1 (Oshiro et al., 2007; Sancak et 
al., 2007; Vander Haar et al., 2007). However, 
knock-down of AKT1S1 impairs the 
phosphorylation of mTORC1-substrates in certain 
cell types, suggesting that AKT1S1 is also important 
for mTORC1 signaling via mechanisms which are 
still incompletely understood (Fonseca et al., 2007; 
Hong-Brown et al., 2010; Wiza et al., 2013a). 
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Figure 3. Primary structure of the AKT1S1 protein and phosphorylation sites. The amino acid numbering refers to protein isoform 
B. 
 
Nucleolar stress response 
Nuclear AKT1S1 binds to the ribosomal protein L11 
(RPL11) (Havel et al., 2014). This interaction is 
dependent on the phosphorylation of Ser221 and 
Thr246 within AKT1S1 (Havel et al., 2014). RPL11 
has been linked to the inhibition of the E3 ubiquitin 
ligase HDM2. This results in increased p53 protein 
stability and activation of the nucleolar stress 
response pathway, which is defined as the activation 
of a specific transcriptional program resulting in cell 
cycle arrest, apoptosis or senescence. The activation 
of this pathway is prevented when RPL11 is bound 
to AKT1S1 (Havel et al., 2014). 
Cell survival 
Akt1S1 protects neurons against cell death following 
spinal cord injury (Saito et al., 2004). 
Overexpression of AKT1S1 in rats reduces infarct 
size following cerebral ischemia (Saito et al., 2006; 
Yu et al., 2008). 
Proteasome activity and insulin sensitivity 
The silencing of AKT1S1 promotes the degradation 
of insulin receptor substrate 1 (IRS1) in skeletal 
muscle through activation of the proteasome (Wiza 
et al., 2013a). As a consequence, the insulin-
mediated activation of IRS1/Akt signaling pathway 
regulating glucose uptake is impaired (Wiza et al., 
2013a). Conversely, overexpression of AKT1S1 
inhibits proteasome activation and increases IRS1 
stability (Wiza et al., 2014). This results in increased 
insulin sensitivity even under conditions of insulin 
resistance. Overexpression of AKT1S1 improves 
insulin signaling via the IRS1/Akt-axis in the heart 
and liver of a high-fat diet mouse model for insulin 
resistance (Völkers et al., 2014). 
Homology 
AKT1S1 homologs in higher species are almost 
identical to human AKT1S1 with conservation of the 
regulatory domains and phosphorylation sites. In 
lower species, like amphibians, fish, and insects, 
proteins almost identical to the carboxy terminus of 
human AKT1S1 have been reported (Wiza et al., 
2012). These proteins show conservation of the 
TOS- and RAIP-motif as well as of the key 
phosphorylation sites equivalent to Ser183 and 
Thr246 of human AKT1S1. Importantly, in D. 
melanogaster, dPRAS40 is also a component of the 
dTORC1-complex, indicating that it is appropriate to 
consider the variants found in these lower species as 
homologs for human AKT1S1 (Pallares-Cartes et al., 
2012; Sancak et al., 2007; Vander Haar et al., 2007). 
Mutations 
No specific mutations in AKT1S1 have been 
associated with pathological conditions. 
Implicated in 
Various cancers 
Multiple cancers and cancer cell lines display 
elevated levels of (phosphorylated) AKT1S1 (Huang 
and Porter, 2005; Jiang et al., 2014). The elevated 
levels of phosphorylated AKT1S1 are mostly found 
in associated with increased activity of kinases 
regulating the phosphorylation of AKT1S1, such as 
Akt, Pim-1 and mTORC1. Nevertheless, some of the 
cellular functions of AKT1S1, such as the regulation 
of the nucleolar stress response, proteasome activity 
and cell survival, suggest that AKT1S1 may 
participate in tumor progression. Finally, 
pharmacological studies have identified 
phosphorylated AKT1S1-Thr246 as suitable 
biomarker to predict the sensitivity to Akt-inhibitors 
in multiple cancers (Andersen et al., 2010; 
Madhunapantula et al., 2011). 
Meningioma 
Immunohistochemical examination of 25 WHO 
grade I and 25 WHO grade II meningiomas showed 
that 56% and 36% of the tumors were positive for 
AKT1S1-Thr246 (Johnson et al., 2009). 
Melanoma 
Phosphorylation of AKT1S1 was increased during 
melanoma tumor progression and closely related to 
elevated Akt3 activity (Madhunapantula et al., 
2007). Knock-down of AKT1S1 decreased 
anchorage-independent growth and increased 
apoptosis in melanoma cell lines (Madhunapantula 
et al., 2007). 
Non-small-cell lung cancer 
In radiation-resistant non-small cell lung cancer 
cells, phosphorylation of AKT1S1 promotes the 
formation of a complex with YWHAZ and FOXO3, 
and the translocation of this trimeric complex from 
the nucleus to the cytosol (Kim et al., 2011). This 
translocation prevents the induction of pro-apoptotic 
genes by FOXO3, such as Bim and FasL. Treatment 
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with PIM-1 kinase inhibitors reduces the levels of 
phosphorylated AKT1S1 thereby increasing the 
amount of nuclear FOXO3 and the radiation 
sensitivity of the non-small cell lung cancer cells 
(Kim et al., 2013; Kim et al., 2011). 
Gastric cancer 
Immunohistochemical examination of 114 gastric 
cancer tumors showed that 45% of the tumors were 
positive for phosphorylated AKT1S1-Thr246. 
Furthermore, phosphorylated AKT1S1-Thr246 
associated with malignant progression and poor 
prognosis of the patients (Lu et al., 2014). 
Type 2 diabetes 
The insulin-mediated phosphorylation of AKT1S1 
on Ser183 and Thr246 in skeletal muscle is increased 
after weight loss in obese patients with type 2 
diabetes, indicating impaired phosphorylation of 
AKT1S1 in patients with type 2 diabetes (Jazet et al., 
2008; Nascimento et al., 2010). 
Diabetic nephropathy 
Glucose-induced phosphorylation of AKT1S1 on 
Thr246 associates with mesangial cell hypertrophy 
in a streptozotocin-induced rat model for type 1 
diabetes, and lipid droplet accumulation in human 
kidney cells (Dey et al., 2010; Hao et al., 2014). 
Diabetic cardiomyopathy 
Overexpression of AKT1S1 protects against the 
development of diabetic cardiomyopathy in mice 
hearts by inhibition of hypertrophy and improved 
insulin signaling (Völkers et al., 2014). 
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